v3.26.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
shares in Thousands
Mar. 31, 2026
Dec. 31, 2025
Current assets    
Cash $ 12,000
Prepaid drug product 474,000 474,000
Other current assets 191,000 193,000
Total current assets 677,000 667,000
Right of use operating assets 11,000
Total Assets 677,000 678,000
Current liabilities    
Accounts payable 5,158,000 4,910,000
Notes payable 511,000 452,000
Accrued expenses 3,020,000 3,004,000
Derivative liabilities 462,000 508,000
Lease liabilities 11,000
Total current liabilities 9,151,000 8,885,000
Warrant liability 12,000 14,000
Total Liabilities 9,163,000 8,899,000
Shareholders' (deficit) equity    
Preferred stock, $.001 par value; 10,000 shares authorized; 51 and 0 shares issued and outstanding, respectively 1,000
Common stock, $.001 par value; 200,000 shares authorized; 9,242 and 5,768 shares issued and outstanding, respectively $ 10,000 $ 9,000
Common stock to be issued 1
Additional paid in capital $ 117,948,000 $ 117,944,000
Accumulated deficit (126,445,000) (126,175,000)
Total shareholders' (deficit) equity (8,486,000) (8,221,000)
Total Liabilities & Shareholders' (Deficit) Equity $ 677,000 $ 678,000